Floatz logo

ABBV-599 COMPONENT UPADACITINIB

Immune Checkpoint Inhibitor-Induced Dermatitis

Shixiu WuSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Immune Checkpoint Inhibitor-Induced Dermatitis cohort.

Asset / SponsorPhaseRating
Tofacitinib
Shixiu Wu
Phase 2CCC

Same molecule, other indications

ABBV-599 COMPONENT UPADACITINIB is also rated in:

Primary Biliary Cholangitis (PBC)Dormant
CCC
Indicative ·
53 / 100
View asset →
Primary Sclerosing Cholangitis (PSC)Dormant
CCC
Indicative ·
53 / 100
View asset →
Atopic Dermatitis (AD)Dormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →